>全球高尿酸血症药物市场，按类型（无症状高尿酸血症、症状性高尿酸血症、其他）、疾病（痛风、肾结石、其他）、药物（热带非甾体抗炎药、黄嘌呤氧化酶抑制剂、选择性尿酸重吸收抑制剂 (SURI)、促尿酸排泄剂、抗痛风剂、碳酸酐酶抑制剂、糖皮质激素、尿酸氧化酶（重组）、碱化剂、其他）、最终用户（医院、家庭护理、专科诊所、其他）、分销渠道（医院药房、网上药房、零售药房）– 行业趋势和预测到 2029 年。
高尿酸血症药物市场分析及规模
预计全球高尿酸血症药物市场在预测期内将出现显著增长。根据美国国家酒精滥用和酒精中毒研究所公布的数据，2011 年平均有 1700 万美国公民患有酒精使用障碍。全球人类的预期寿命不断增加，导致老年人口增加。这一趋势导致这种疾病的发病率和人均治疗需求增加，从而对行业产生积极影响。
Data Bridge Market Research 分析了 2022-2029 年预测期内全球高尿酸血症药物市场的增长率。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。
高尿酸血症药物市场范围和细分
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020（可定制为 2014 - 2019） |
|
定量单位 |
收入（单位：十亿美元）、销量（单位：台）、定价（美元） |
|
涵盖的领域 |
类型（无症状高尿酸血症、症状性高尿酸血症、其他）、疾病（痛风、肾结石、其他）、药物（非甾体抗炎药、黄嘌呤氧化酶抑制剂、选择性尿酸重吸收抑制剂 (SURI)、促尿酸排泄剂、抗痛风剂、碳酸酐酶抑制剂、糖皮质激素、尿酸氧化酶（重组）、碱化剂、其他）、最终用户（医院、家庭护理、专科诊所、其他）、分销渠道（医院药房、网上药房、零售药房） |
|
覆盖国家 |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland) |
|
Market Opportunities |
|
Market Definition
Hyperuricemia is the type of condition wherein an excessive level of uric acid is produced in the blood. The level of uric acid in the blood is the balance between the breakdown of purines and the rate of uric acid excretion. The alteration in the uric acid level may cause hyperuricemia. High uric acid can result in serious diseases such as painful arthritis called gout. Nearly 43.3 million Americans have hyperuricemia and gout conditions.
Global Hyperuricemia Drugs Market Dynamics
Drivers
- Availability of Advanced Treatment Procedures
With each decade, varied treatment methods are available to help the patients' faster recovery. Treatment advancements in terms of hearing aids, corrective lenses are on the rise. Thus, it acts as a major driver in the market growth.
- Increasing Incidence in Elderly Population
Myelofibrosis cases are mostly witnessed in the age group ≤ 40 years, 41−60 years, and > 60 years. The >60 years group saw highest number of patients mostly around 10,275 in 2021 in the U.S. In 2021, eligible treatment population of myelofibrosis accounted for 9,511 cases in the U.S. Thus, this elderly population with higher chances of getting this disease boosts the market growth.
Opportunities
- Rising R&D and New Drug Approvals
Numerous clinical trials are carried out by several research institutes and companies in order to discover most efficient drug for rearming the disorder. For instance, Ardea Biosciences, Inc. is conducting phase 2 clinical trials for testing the efficiency of RDEA806 for treatment of hyperuricemia. Hebei Medical University is conducting phase 3 trials to test the hypothesis that prednisone is superior over allopurinol in renal function improvement in heart failure patients with hyperuricemia. TWi Biotechnology, Inc. was awarded with U.S. patent in 2014 for AC – 201 which is effective in treating hyperuricemia.
- Increasing Collaborations and Market Expansion
一些在市场上运营的大型公司坚持合作发展、扩大产品组合和在发展中市场进行区域扩张。这些市场参与者的主要战略任务是增加市场份额。因此，这些因素正在推动市场增长。
限制/挑战
- 缺乏意识
缺乏对这些疾病的认识以及缺乏大量宣传计划阻碍了市场的增长。现有药物尚未显示出改善疾病的活性，并且仍然不足以满足主要未满足需求。
- 成本高
与这些药物相关的巨额开支阻碍了市场的增长。庞大的药物开发和相关流程阻碍了市场的增长。
这份全球高尿酸血症药物市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新。如需了解有关全球高尿酸血症药物市场的更多信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。
全球高尿酸血症药物市场范围
全球高尿酸血症药物市场根据类型、疾病、药物、分销渠道和最终用户进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
类型
- 无症状高尿酸血症
- 症状性高尿酸血症
- 其他的
疾病
- 痛风
- 肾结石
- 其他的
药物
- 非甾体抗炎药
- 黄嘌呤氧化酶抑制剂
- 选择性尿酸重吸收抑制剂 (SURI)
- 促尿酸排泄剂、抗痛风剂
- 碳酸酐酶抑制剂
- 糖皮质激素，尿酸氧化酶（重组）
- 碱化剂
- 其他的
最终用户
- 医院
- 家庭护理
- 专科诊所
- 其他的
分销渠道
- 医院药房
- 网上药店
- 零售药店
高尿酸血症药物市场区域分析/见解
对全球高尿酸血症药物市场进行了分析，并按类型、疾病、药物、分销渠道和最终用户提供了市场规模洞察和趋势。
全球高尿酸血症药物市场报告涉及的主要国家 有：北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区（APAC）其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲（MEA）其他地区、南美洲的巴西、阿根廷和南美洲其他地区。
由于政府和制药组织采取越来越多的举措来提高仿制药制造商的知名度和影响力，亚太地区在整个预测期内全球高尿酸血症药物市场一直呈现积极增长。
由于肾脏疾病技术的进步和制药组织为开发新配方而采取的不断增多的举措，北美占据了市场主导地位。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
竞争格局和全球高尿酸血症药物市场份额分析
全球高尿酸血症药物市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对全球高尿酸血症药物市场的关注有关。
全球高尿酸血症药物市场的主要参与者包括：
- 辉瑞公司 (美国)
- F. Hoffmann-La Roche Ltd（瑞士）
- Mylan NV（美国）
- 费森尤斯卡比公司（德国）
- Hikma Pharmaceuticals PLC（英国）
- 诺华公司（瑞士）
- Teva Pharmaceutical Industries Ltd.（以色列）
- 百时美施贵宝公司 (美国)
- 葛兰素史克公司（英国）
- 拜耳公司（德国）
- 太阳制药工业有限公司 (印度)
- Dr. Reddy's Laboratories Ltd（印度）
- Endo International plc（爱尔兰）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
